SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

GODAVARI DRUGS

BSE: 530317 28 Jun 2025
Healthcare
₹ 94.5
Godavari Drugs Ltd. specializes in Pharmaceuticals within the Healthcare sector.

GODAVARI DRUGS - Share Price & Details

Market Cap
₹70.0
High /Low
155.0 / 79.0
Stock P/E
16.0
Book Value
₹57.6
Dividend Yield
0.0
ROCE
10.3
ROE
₹10.6
Face Value
10.0
PEG Ratio
0.94
EVEBITDA
₹10.1
Debt
61.6
CMP / FCF
312.0
Debt to equity
₹1.42
NP Ann
4.38
High price all time
155.0
Piotroski score
₹5.0
Graham Number
86.8
No. Eq. Shares
0.75
Net CF
₹-0.25
Net profit
4.38
Price to book value
1.61
Interest Coverage
₹2.19
Low price all time
2.61
Industry PE
32.7
Reserves
₹35.8
Free Cash Flow
₹-8.80

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
GODAVARI DRUGS LTD.NANANANA70.016.0
VIVO BIO TECH LTD.NANANANA67.99.33
VASUNDHARA RASAYANS LTDNANANANA65.515.4

Peer Comparison Chart


About GODAVARI DRUGS

Godavari Drugs Ltd., with Security Code 530317, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Godavari Drugs standalone net profit declines 66.54% in the March 2025 quarter

(30 May 2025)
Sales decline 34.01% to Rs 25.50 crore. Net profit of Godavari Drugs declined 66.54% to Rs 0.89 crore in the quarter ended March 2025 as against Rs 2.66...
Read more →

Godavari Drugs Reports Significant Decline in Profitability and Sales for March 2025

(30 May 2025)
Godavari Drugs has announced its financial results for the quarter ending March 2025, revealing a significant decline in Profit After Tax (PAT) to Rs 1.66...
Read more →

Avantel alltos 2.02 cr equity shares under rights issue

(30 May 2025)
Consequent to the said allotment, the paid-up equity share capital of the company stands increased to 26,49,61920 equity shares of Rs 2...
Read more →

AstraZeneca Pharma receives marketing approval for Benralizumab in India

(30 May 2025)
AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health...
Read more →

Apollo Ingredients standalone net profit declines 5.88% in the March 2025 quarter

(30 May 2025)
Sales decline 31.00% to Rs 0.69 crore. Net profit of Apollo Ingredients declined 5.88% to Rs 0.16 crore in the quarter ended March 2025 as...
Read more →

Q4 Results Today: Suzlon, SJVN, Mazagon Dock, Bajaj Auto, Ola Electric Among 550+ Companies To Report Earnings

(29 May 2025)
As many as 555 companies are scheduled to share their Q4FY25 results for the quarter and the financial year ended March 2025 on Thursday.
Read more →